Preface:
Although considerable progress has been made in the field of stem cell transplantation in pediatric hemato-oncology, relapse of the underlying disease has remained a major cause of treatment failure. Successful post-relapse therapy in patients with acute leukemias and advanced myelodysplastic syndrome (MDS) who received allogeneic stem cell transplantation (allo-SCT) is mainly restricted to a second allograft with considerable treatment related mortality (TRM). Therefore great efforts have been undertaken to identify patients with highest risk for post-transplant relapse using PCR-based technologies. Two different approaches can potentially identify these high-risk patients: i) characterization of hematopoietic chimerism and ii) analysis of minimal residual disease (MRD).
Summary:
In the first contribution, PD Dr. P. Bader (Tübingen, DE) presented a large prospective multi-center trial focusing on 163 children with ALL in whom chimerism was serially assessed in whole peripheral blood at high frequency (weekly during the first 100 days, thereafter once a month). Additional immunotherapy was offered to those patients who developed increasing mixed chimerism (in-MC). The otherwise fatal outcome of this patient group could be improved to an EFS of 38%. Analysis of chimerism in leukocyte subpopulations may be of additional value, because this improves the limited sensitivity of the technique. This was demonstrated by Prof. Th. Lion (Vienna, AT), who presented a prospective trial in which chimerism was assessed within different hematopoietic lineages. Indeed a higher sensitivity was obtained and MC could be detected in all patients before relapse or graft rejection. However, an algorithm to predict which patients will definitively relapse or reject their grafts could not be found. In a smaller study Dr. D. Turkiewicz (Wroclaw, PL) could confirm the importance of serial chimerism investigations in peripheral blood. Dr. W. Hoelle (Tübingen, DE) presented a prospective trial in children transplanted for severe aplastic anemia (SAA) and could show that low dose donor-lymphocyte infusion can convert MC back to complete chimerism (CC) and thereby avoid graft rejection in patients with rapid recurrence of host derived hematopoietic cells. PCR-based detection of MRD in children with acute lymphoblastic leukemia (ALL) is technically more complex than analysis of post-transplant chimerism. At present, PCR analysis of immunoglobulin-and T-cell receptor gene rearrangements serves as the gold standard for MRD detection in patients with ALL. In his presentation, Prof. J.J.M. van Dongen (Rotterdam, NL) detailed the urgent need for standardized multi-center trials because of the complexity of PCR-based MRD techniques. He showed, that under his coordination an European Study Group on MRD detection in ALL has been founded and will provide the scientific community with reliable prospective data in the near future. Dr. C. Eckert (Berlin, DE) presented a retrospective study in which she could show, that standardized MRD detection in children with relapsed ALL can serve as a diagnostic tool for improved identification of patients that might benefit from SCT. In patients with acute myeloid leukemia (AML) and advanced MDS the determination of MRD is more difficult due to the fact that a uniform technique is not yet available. Prof. A. Biondi (Monza, IT) presented a new real-time-PCR approach for the detection of Wilms tumor gene 1 (WT-1) transcripts, which are highly expressed in virtually all patients with AML, advanced MDS, and JMML. As the WT-1 gene is also expressed in normal CD34 progenitor cells, the detection of MRD using this approach might be restricted to analysis of peripheral blood.
Conclusions:
So far the serial and quantitative analysis of hematopoietic chimerism in peripheral blood could identify patients at highest risk of relapse. Moreover chimerism studies provide a basis for additional immunotherapy to prevent relapse in malignant diseases and to prevent graft rejection in non-malignant diseases. Formally, chimerism studies can not discriminate between imminent relapse and graft rejection. However, this can be evaluated by standardized MRD techniques, which are now available for virtually all ALL patients and 30-40% of AML patients. Prospective data on the clinical impact of posttransplant MRD detection are not yet generated, but will be available in the near future.
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The French experience with HDC/PSCR in high risk CNS tumours in children. Summary and conclusions on indications and type of HDC in 2002 D. Valteau, C. Kalifa, J Grill, E Benhamou O. Hartmann (Villejuif, F) Poor prognosis of certain types of central nervous system (CNS) tumours and unacceptable long term sequelae of radiotherapy, especially in young children led to develop new treatment strategies in paediatric brain tumours. In this respect, there has been much recent interest in the use of HDC followed by autologous stem cell transplantation (ASCT). Alkylating agents appear the most appropriate class of drugs to be used in a high-dose setting, since they are among the most active drugs against CNS tumours and are characterized by a step linear-log response relationship. At Institut Gustave Roussy, Villejuif, we have mainly used a combination of Busulfan and Thiotepa. Thiotepa and its major metabolite, TEPA, reach cerebrospinal fluid (CSF) concentrations that are approximately equivalent to the plasma concentrations at the same time. They show in vitro cytocidal activity with a steep dose-response curve against medulloblastoma and glioma CNS tumour cell lines. Busulfan crosses the brain blood barrier with a CSF to plasma ratio of 1.39 when given a dose of 600 mg/m 2 . Recently, we showed that busulfan displayed anti tumour activity against medulloblastoma xenografts in athymic nude mice. Busulfan is administered orally every 6 h at a daily dose of 150 mg/m 2 for 4 consecutive days. Thiotepa is given as an 1-h infusion at a dose of 300 mg/m 2 /day for the next 3 days. ASCT is performed 48 hours after completion of HDC. Busulfaninduced seizures are prevented by the use of clonazepam. The specific toxicities of this regimen are cutaneous toxicity with erythro-melanodermia, severe gastrointestinal toxicity, the incidence of hepatic veno-occlusive disease is lower than after the combination of Busulfan with Melphalan. The toxic mortality rate of this HDC regimen is <10% and improved with time. Contrast enhancing lesions in the radiation fields on MRI were observed in 25% of the patients associated in half of them with worsening of the cerebellar syndrome and signs of increased intracranial pressure. We have evaluated this regimen in different histological types of tumours. Sixteen patients with ependymoma were treated in the SFOP Group. Eight of them had previously received irradiation at the tumour site, the 8 others, <3 years at diagnosis were treated with postoperative conventional chemotherapy. Tumour response was valuable in 15 patients. Stable disease and progression was documented in 10 and 5 cases respectively. As with the CCG protocol using a combination of Etoposide, Thiotepa +/-Carboplatine, no tumour response or prolonged survival was attributable to HDC (1). This HDC, administered 2 to 3 months after focal radiotherapy in 24/35 eligible patients with brainstem glioma failed to improve their median survival time (10 months, range 3-26). This aggressive treatment modality did not appear to be any better than that reported with conventional radiotherapy (2). In children <3years with a local relapse of a medulloblastoma after surgery and conventional chemotherapy , the 5-year EFS of a treatment with Busulfan -Thiotepa followed by ASCT and irradiation limited to posterior fossa is 80%. This result led us to increase the age limit for a chemotherapy -based strategy to 5 years. Prognosis of young patients with metastatic medulloblastoma treated occordint to this strategy remained poor. We thus developed for this group of patients an aggressive therapeutic schedule. After surgery, patients were planned to receive 2 courses of etoposide (500 mg ) these 3 courses were followed by ASCT, and an irradiation of posterior fossa alone. Eighteen patients entered this program, tumour response was valuable in 13/16 who received the whole treatment , 4 CR and 9 PR were observed. Four patients are alive with a 5 year median follow-up. However, a very high visceral toxicity was observed after the last course with 3 toxic deaths and 6 pulmonary haemorrhage and 9 hepatic veino-occlusive disease. Despite the very high response rate and the improvement in survival this approach appeared too toxic. A strategy with a less dose-intensity of alkylating agents is on progress in young patients with metastatic medulloblastoma and PNETs (3). HDC for treatment of paediatric CNS tumours displayed promising results as a means of avoiding devastating sequelae of CNS irradiation in young children with medulloblastoma. Much work is still required to define the optimal HDC for each tumour type. The full impact of HDC in terms not only of survival but also quality of life of children with CNS tumours must be determined by prospective collaborative national and international studies.
S. Dallorso, L. Rivabella, G. Cefalo, C. Milanaccio, F. Porta, G. Morreale, B. Cappelli, M. L. Garrè (Genoa, Milan, Brescia, I) HD therapy with stem cell rescue is part of up-front treatment for high-risk infants malignant CNS tumours. In 1997 we started a two phases chemotherapy protocol (Phase A= induction, B= double PBPC transplantation), carried out in 20 children with high risk features (poor histology, incomplete resection, metastasis or recurrent disease), younger than 5 years and weighing < 20 kg, suffering from Medulloblastoma (8), PNETs (5), miscellaneous (7). PBPC collection was performed during Phase A, with G-CSF 10/kg/day stimulus, after high dose Etoposide and/or Cyclofosfamide. Collection was carried out when the value of circulating CD34+ cells was higher than 40L, median 187, (53-484), using a monolumen catheter and a peripheral access. 9 pts. underwent 1 collection, 8 pts. 2 collections, 2 pts. 3 and one child a total of 5 apheresis. The median number of collected CD34+ was 16.5 x 106 /kg (4, . The blood volume processed was 2445 ml , the blood withdrawal was 22 ml/min (16-27). Responding patients underwent two consecutive high dose conditioning regimens (Carboplatin 1500 mg/m2 + Etoposide 500-600 mg/m2 followed at recovery by Thiotepa 30 mg/kg + Melphalan 4 mg/kg) with PBPC reinfusion (Phase B). Radiotherapy (Phase C) was administered in case of residual disease or metastasis or poor histology if 3 yrs old. The median number of CD34+/kgx106 infused was 7.5 (4 to 18) after the 1st cycle and 7.5 (2 to 18) after the 2nd. PMN recovery (> 0.5x109/L) was achieved at a median time of 12 days (7 to 30) in the former group and of 11 days (9 to 29) in the latter group. Last platelet and red blood cell infusion occurred on day 8 and 8 (6 to 14 and 4 to 14) in the first group, and on day 10 and 8 (7 to 32 and 2 to 34) in the second group. Outcome: 1) the Phase A induces mobilisation of a great amount of CD34+ cells 2) the 1st HD course has a very low toxicity, 3) the haematological and mucosal toxicity of the 2nd cycle is higher but acceptable, 4) 8 children received radiotherapy after transplantation, 5) 2 pts. progressed before high-doses (1 died, 1 AWD), out of the 17 patients receiving the double PBPC 10 are in CR, 1 with residual disease, 1 with PD, 5 pts. died of disease), 1 patient is waiting for the 2nd cycle. Our experience shows that collection of PBPC has a high rate of efficacy and that a double PBPC transplant is safe, feasible and more active than conventional therapy in high risk patients.
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High-dose chemotherapy with autologous stem cell rescue in childhood medulloblastoma. Experience in five Spanish hospitals P. Galaron, C. Calvo, A. Fernandez-Teijeiro, M. Couselo, J.L. Vivanco, M.E. Cela, M.A. Cantalejo (Madrid, Bilbao, Santiago de Compostela, E) Objective: To evaluate ten children with recurrent or high-risk medulloblastoma/PNET treated with high-dose chemotherapy followed by autologous stem cell rescue (ASCR). Methods: Since April 1998 until April 2002, ten patients (6 males, 4 females) with relapsing medulloblastoma (5 in first relapse, 3 in second relapse) or metastatic disease at presentation were evaluated, aged 3-14 years at diagnosis (median 8 years), and 3-20 years at ASCR (median 10 years). All have been previously treated according to PNET-STUDY III SIOP protocol, and were in complete remission or very good partial response, except two of them, one in progressive disease and the other in partial response. The source of transplantation was peripheral blood stem cells and the median of infused CD34+ cells was 7.35x10^6 (range 1.71-32). Conditioning regimen consisted of Carboplatin, VP-16 and thiotepa in 8, and Busulfan and thiotepa in 2. Results: 9/10 patients had neutrophil engrafment at day 10 (median) and platelets at day 18. One early toxicity-related death ocurred in a patient (day 18) without engrafment by multiorgan failure, neutropenic enterocolitis, renal and hepatic failure and toxic encephalopathy. All patients had fever during neutropenia and mucositis, grading III in 8/10. An infection was
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Viridans and E.Coli) and 2 pneumonia (1 Hemophillus Influenzae). One patient had skin toxicity grading IV and 1 patient adult respiratory distress syndrome, multifactorial encephalopathy and toxic hepatitis (grading III). At the end of the period of study, 3 patients are alive, two in complete remission (both of them 36 months postASCR) and one in stable disease (21 months postASCR). Six out of nine patients evaluable had died secondary to progressive disease with a median time to relapse of 6.6 months (range 2-12) after transplant. Conclusions:1-ASCR is an encouraging therapeutical option in this group of patiens with poor prognosis 2-Our toxicityrelated death had been 10%, similar to others groups While autologous stem cell transplantation has become a standard procedure for a variety of solid tumors, novel indications for selected pediatric brain tumors are emerging. We present first data from a German HIT-based study protocol using a carboplatin-thiotepa-etoposide (CET) based conditioning regimen with or without the intraventricular application of methotrexate followed by transplantation of autologous peripheral stem cells. Data from this pilot study as well as from other international study groups have provided the rationale for integrating HDCH and autologous stem cell transplants for patients with high-risk medulloblastoma in the new brain tumor study protocol of the GPOH (HIT 2000).
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Definition of the high risk patients: the EBMT-CWS experience and CWS proposal for a therapeutic strategy for high risk sarcoma patients E. Koscielniak, R. Handgretinger, D. Dilloo, G. Rosti, D. Niethammer, J. Treuner, T. Klingebiel (Stuttgart, Dusseldorf, Tubingen, Frankfurt, Stuttgart D; Memphis, USA; Ravenna, I) Patients with primary metastatic tumors represented ca. 20% of patients with rhabdomyosarcoma-like (RMS, Ewing sarcoma family of tumors and undifferentiated sarcoma) registered in the German Cooperative Soft Tissue Sarcoma Studies CWS-81,-86, -91 and -96. The five year survival rate among these patients is low -20-30% -despite the use of intensive chemotherapy with or without haematopoietic stem cell rescue (HR). In the ongoing German Study CWS-96, the CEVAIE regimen (carboplatin, vincristine, ifosfamide, VP16, epirubicine) followed by two therapy options: double high dose chemotherapy (HDC-cyclophosphamide/thiotepa and melphalan/VP16) with stem cell rescue (HR) or oral maintenance therapy with VP16/idarubicin and trophosphamide is recommended. A preliminary analysis did not show any prognostic advantage of the HDC. The median time to relapse in patients with clinical remission after double high dose chemotherapy (HDC) was 5.7 months (3-9 months). In comparison, the median time to relapse in patients who did not receive HDC was 7 months. The major cause of treatment failure was recurrent malignancy, presumably related to incomplete eradication of the disease, since in the majority of patients the disease recurred in one of the previous known tumor sites. The theory that reinfusion of contaminated progenitor cells as a cause of disease recurrence is possible but remains controversial . There is now little doubt that the increase in the dose intensity is feasible with HR, but better response, as measured by reduction of tumor mass, cannot always be translated into better survival. The prognostic relevant factors in 201 patients with primary metastatic tumors treated according to the CWS-Studies -81, -86, -91 and -96 were: age ( 10 yrs -p<0.003) and bone/bone marrow metastases (p<0.014). Patients with Stage IV, 10 yrs with B/BM metastases had a S rate at 5 yrs of 6±4%. In contrast the outcome of metastatic patients <10 yrs of age without B/BM metastases was much better with a cure rate of 41±7%. Histology, single vs. multi organ metastases and consolidation with HDC were not related to prognosis. The multivariate analysis of the 269 patients with metastatic RMS who were registered in the EBMT Registry or in the German/Austrian/Swiss Pediatric Stem Cell Transplantation Registry and were treated with HDC revealed similar factors: age ( 10yrs, p<0.0001) and B/BM involvement (p<0.019) as most important predictor for fatal outcome. The 3 yrs EFS-rate for 78 patients with B/BM metastases of RMS or EES/PNET registered in the German CWS-81-91 Studies (60) and/or EBMT registry, was 9%. The S rate in pts with HDC was 16%, in pts without HDC 6% (p<0.01). Similar poor prognosis had patients with alveolar RMS and all patients with RMS-like tumors, who developed metastatic or combined relapse. The 5 yrs EFS-rates are 8% and 6% respectively . Thus it became evident that neither the conventional dose escalation nor the intensification of chemotherapy with a dose level which requires HR altered the prognosis of patients with primary metastatic STS, especially the high risk group with B/BM metastases, or patients with metastatic relapse.Therefore, identification of novel strategies which could eradicate chemotherapy-resistant tumor cells is needed. We decided to design several therapeutic approaches to find out whether residual tumor cells can be eradicated by autologous or alllogeneic cellular immuntherapy and/or by prolonged low dose chemotherapy. Many types of soft tissue sarcomas are characterized by specific chromosomal translocations which are likely to be of etiological significance therefore may be regarded as target for immunotherapeutic approaches. Allogeneic transplantation avoids the risk of reinfusion of malignant cells, and potentially a graft-versus tumor effect may occur in addition to the cytoreduction from high dose chemotherapy. However, not all patients have an HLA-identical donor, preferably (since an experimental therapeutic approach) > 18 yrs old. Recently the peripheral allogeneic, not fully HLA-compatible stem cells mobilized with cytokines and highly purified have been established as a very promising source of hematopoietic progenitors. This type of hematopoietic rescue has several advantages over conventional sources for many reasons: 1. High numbers of progenitors available 2. Facilitating of engraftment across the MHC barrier by 10-60 fold doses of CD34+ cells 3. Avoidance of GVHD (without immunosuppressive therapy) but maintaining graft-vs.tumor effects 4. Rapid and functionally competent reconstitution of the T-, B and NK-compartment in pediatric recipients 5. Novel graft versus tumor effector mechanism, unique to HLA haplotype-mismatched stem cell transplant 6. Possibility of adoptive transfer of donor effector cells. The new strategy for patients with RMS-like high risk sarcoma includs the same induction therapy for all patients followed by different therapeutic options according to the risk factors. The induction therapy is based on the CEVAIE (six drugs) regimen with up front window application of Topotecan (1mg/m²/day as 24hr Infusion) and Carboplatin (150mg/m²/day) as a 4 hr infusion for 4 days. Surgery and radiotherapy should be done according to the standard CWS recommendations. As a consolidation therapy several experimental therapeutic options will be evaluated : 1. High dose busulfan contained therapy with autologous HR and vaccination with autologous DC cells 2. oral maintanance therapy 3. alloimmuntherapy with reduced intensity conditioning and HLA-matched related donor (common EBMT, PWP and STWP study) 4. chemo-alloimmuntherapy (busulfan contained dose-intensive regimen) and HLA-matched or 1-3 loci mismatched familiar donor. Since the chimeric genes can be used as genetic markers in highly sensitive PCR based assay for detecting minimal metastatic (MMD) and residual disease (MRD) in biological samples we will include this type of monitoring for all patients with translocation positive sarcomas. It is interesting to evaluate whether the molecular remission status could be significant in monitoring adjuvant therapies.
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Experience within the SIOP CNS GCT 96 trial/SFOP studies with HDC/SCR in patients with CNS germ cell tumours and further implications for high risk patients
G. Calaminus, C. Patte on behalf of the SIOP/SFOP working groups
Objective: In ongoing protocols worldwide the frequency of relapses in malignant CNS GCT under platinbased treatment regimen can be estimated as about 15% for germinoma and 30% for secreting CNS GCTs. Recurrent malignant intracranial CNS Germ Cell tumors especially if of non-germinomatous histology carry a poor prognosis. According to experience of published series nearly all patients with recurrence after a nongerminomatous CNS GCT died. Therefore the attempt of recent protocols is to evaluate treatment strategies for recurrent malignant CNS GCT to achieve better overall outcome results. Within the SFOP (Sociėtė Francais d'Oncology Pediatrique) protocols of the 90ies, 73 patients with germinoma were treated. In SIOP (Societe International D'Oncology Pediatrique) CNS GCT 96, 150 protocol patients with germinoma were registered. For secreting tumors (YST, CHC, EC ) 38 patients were protocol patients in the SFOP studies and 109 in SIOP CNS GCT 96. Patients and initial treatment: In the SFOP studies all patients with germinoma received a combined treatment with 2 courses Carbo/VP16/Ifosfamid followed by radiotherapy (RT), which was focal (40 Gy) in localized disease or craniospinal (CSI) in metastatic disease. In SIOP CNS GCT 96 pts were either treated with chemo (CT) and focal RT equally to the SFOP studies or receive craniospinal RT (24/16 Gy). For secreting tumors in the SFOP studies patients received 4-6 courses CT followed by focal RT (54 Gy) or CSI (30/24 Gy ) in metastatic disease. Some of the patients (TGM95) had CT alone, to evaluate the remission rate with CT only. In SIOP CNS GCT96 all pts with localized tumors were treated with 4 courses Cisplatin/VP16/Ifos-famide followed by focal RT (40Gy) in localized tumors and by CSI (30/24Gy) in disseminated disease. Profile of patients with recurrence: Germinoma: Within the SFOP studies for germinoma, 9 relapses occured, 8 in pts with localized disease and one in a pt with disseminated tumor. 6 pts had ventricular relapses, one a local, one a spinal relapse and one a recurrence outside the ventricles. All were treated with conventional therapy (VP16/Carbo, VIP) to achieve again a biological remission, which was possible in 7 pts, one had a inoperable tumor residuum and one show only partial response. In SIOP CNS GCT96, 8 relapses occurred, 4 after combined treatment and 4 after CSI. All were treated with chemotherapy again (PEI or VP16/Carbo), all responded very well, 7/8 achieved complete biological remission. One had a tumor residual which came out to be mature teratoma. Secreting tumors: In the SFOP studies 10 relapses were reported. 7 had spinal relapses, combined with intracranial lesions in 3. Three were local (2) or ventricular (1). All received additional chemotherapy VP16/DDP or VIP. Biological remission was obtained in 7 pts. In SIOP CNS GCT 96, 25 relapses occurred. Relapses were mainly local (14), spinal (4) and combined (local and spinal: 6), one had an abdominal relapse. Also in this cohort additional platinbased chemotherapy led to a complete or nearly complete biological response. Patients with High dose treatment: Germinoma: 8/9 of the SFOP series received high-dose treatment (HDC) with VP16/Thiotepa, two cycles (VP16 3x500 mg/m2, Thiotepa 3x300 mg/m2). 4 achieved a long term remission, 4 relapsed again, of whom 1 died and 2 were salvaged by HDMTX and RT and one is under third line treatment. Within the SIOP Protocol in germinoma 3/8 relapsing patients had high dose treatment with Carbo/VP16/Thiotepa; VP16/Thiotepa. 2/3 are alive the other 5/8 had irradiation after conventional treatment. 3 survived , two died of disease. Secreting tumors: 7/10 relapsed pts in SFOP received HDC after recurrence and second line treatment. 3 are alive after VP16/Thiotepa. In SIOP CNS GCT96 9/25 received HDC. 2 are in remission, 2 have just finished their treatment. Side effects: Reported side effects were moderate with panzytopenia and mucositis. Conclusion: HDC in recurrent CNS GCT is a possible treatment option when biological remission is achieved prior to HDC. In the new SIOP protocol HDC will be used within the first line in patients with insufficient response to primary chemo. 
C. Uderzo on Behalf of EBMT PWP and I-BFM-SG (Monza, I)
Summary : Despite very intensive first line protocols the results concerning the treatment of Childhhod VHR ALL have been relatively dismal . Different combinations of risk factors at the diagnosis were used to design first-line protocols and this variable strategy reflects statistical variation on event free survival obtained by single or multicenter studies in this particular cathegory of patients. Since 1995 the EBMT and I-BFM-SG set up a prospective randomized trial with the aim to compare the role of AlloBMT vs.CHEMO in the treatment of VHR childhood ALL. The homogeneous criteria adopted in defining VHR patients at diagnosis were as follows: cytogenetic abnormalities as t(9;22) or t(4;11), Prednisone poor response and T-ALL or WBC more than 100.000/mm3, induction failure. Patients having a suitable HLA A,B,DR sibling donor underwent AlloBmt as soon as they obtained the 1st CR. Relevant features of this study covered an area of particular interest by a multicenter study ( 392 VHR ALL patients recruited in 5 years with a median follow up of 50 months) based also on common BFM "first line protocol" and on prospective HLA typing (allowing a "biological randomization") which was performed at the time of the attainment of the first complete remission (CR). The main goal of this cooperative study was to recruit a sufficient number of patients in order to perform an intention to treat analysis and to overcome the selection bias regarding the allocations to transplant and chemotherapy . The final analysis is underway and will be presented within the 2002. The preliminary result yelds an extremely high participation to the study ( 92% of the recruited patients, i.e.360/392, are evaluable for the analysis). Looking at the assigned arm by genetic chance 267/ 360 performed chemotherapy (20/267 despite an available sibling donor), 50/360 underwent an AlloBmt from sibling donor, 26/360 underwent a MUD BMT and 17/360 an alternative donor BMT . The 5 years overall survival ( 53%) and DFS (44%) promt the participating Centers to continue to improve in the future the strategies for the VHR ALL children. The significative advantage for donor versus "no donor" cohort of patients ( 5 years DFS = 58% vs 40% respectively) outlines the importance of the intention to treat analysis in this intergroup large study. As a matter of fact some deviations from the study in that some patients performed also a match/mismatch unrelated donor BMTs or alternative donor BMT have been adjusted and correctly evaluated only by this particular approach.
